PDGF-A, PDGF-B, TGFβ, and bFGF mRNA levels in patients with essential thrombocythemia treated with anagrelide

✍ Scribed by Paola R. Lev; Juan P. Salim; Laura I. Kornblihtt; Carlos J. Pirola; Rosana F. Marta; Paula G. Heller; Felisa C. Molinas

• Publisher: John Wiley and Sons
• Year: 2005
• Tongue: English
• Weight: 61 KB
• Volume: 78
• Category: Article
• ISSN: 0361-8609
• DOI: 10.1002/ajh.20268

✦ Synopsis

Plasmatic levels of PDGF-AB, TGFb 1 , and bFGF are increased in patients with essential thrombocythemia (ET) while intraplatelet levels are low for PDGF, normal for TGFb, and elevated for bFGF. To evaluate the contribution of gene expression to the dysregulated cytokine levels, we studied platelet PDGF-A, PDGF-B, TGFb 1 , and bFGF mRNA in ET patients before and during anagrelide treatment. We found decreased PDGF-A and PDGF-B, increased TGFb 1 , and normal bFGF mRNA levels. During treatment, mRNA levels remained decreased for PDGF-A, were increased for PDGF-B and normal for TGFb 1 . In untreated patients, protein expression of PDGF paralleled its mRNA levels while different patterns of RNA and protein were found for TGFb 1 and bFGF.